Efficacy of Azacitidine in de Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study

Conclusions Treatment with azacitidine led to a median overall survival of 10 months in both, a previously untreated and a previously treated frail AML patient cohort. A positive effect in transfusion dependency was observed in 29% of these patients and was associated with better survival. Teaser Azacitidine is a treatment option for patients with acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy. It is still unknown which patients will benefit most from azacitidine treatment. Therefore, we conducted a retrospective comparative study on forty patients with newly diagnosed and relapsed AML. We found no significant difference in overall survival time (10 months) between these two patient groups. Prior treatment does not predict poor outcome. Achievement of transfusion independency was associated with longer survival.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research